|
WO1983001451A1
(en)
|
1981-10-23 |
1983-04-28 |
Molecular Biosystems Inc |
Oligonucleotide therapeutic agent and methods of making same
|
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
|
EP0348458B1
(en)
|
1987-11-30 |
1997-04-09 |
University Of Iowa Research Foundation |
Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US5965722A
(en)
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US6831166B2
(en)
|
1992-10-23 |
2004-12-14 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
|
KR940703846A
(ko)
|
1991-12-24 |
1994-12-12 |
비. 린네 파샬 |
갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
|
|
US20060270624A1
(en)
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
TW244371B
(enExample)
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
|
AU678769B2
(en)
|
1992-07-27 |
1997-06-12 |
Hybridon, Inc. |
Oligonucleotide alkylphosphonothioates
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
AU6165494A
(en)
|
1993-01-25 |
1994-08-15 |
Hybridon, Inc. |
Oligonucleotide alkylphosphonates and alkylphosphonothioates
|
|
US5734039A
(en)
*
|
1994-09-15 |
1998-03-31 |
Thomas Jefferson University |
Antisense oligonucleotides targeting cooperating oncogenes
|
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
KR19990082476A
(ko)
|
1996-02-14 |
1999-11-25 |
하우스 한스 루돌프, 긴터 베아트리체 |
당-변형되어 갭이 형성된 올리고뉴클레오티드
|
|
US6015710A
(en)
|
1996-04-09 |
2000-01-18 |
The University Of Texas System |
Modulation of mammalian telomerase by peptide nucleic acids
|
|
US20080119427A1
(en)
|
1996-06-06 |
2008-05-22 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5912332A
(en)
*
|
1996-07-26 |
1999-06-15 |
Hybridon, Inc. |
Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
|
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
WO1999054459A2
(en)
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
EP0979869A1
(en)
|
1998-08-07 |
2000-02-16 |
Hoechst Marion Roussel Deutschland GmbH |
Short oligonucleotides for the inhibition of VEGF expression
|
|
US6228642B1
(en)
|
1998-10-05 |
2001-05-08 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
KR20000065690A
(ko)
|
1999-04-08 |
2000-11-15 |
박종구 |
반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
|
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
|
IL148916A0
(en)
|
1999-10-04 |
2002-09-12 |
Exiqon As |
Design of high affinity rnase h recruiting oligonucleotide
|
|
AU3041701A
(en)
|
1999-12-23 |
2001-07-09 |
Exiqon A/S |
Therapeutic uses of lna-modified oligonucleotides
|
|
US6602857B1
(en)
|
2000-01-18 |
2003-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
|
DE60110244T2
(de)
|
2000-09-06 |
2006-01-19 |
Mcgill University, Montreal |
Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribosenukleotide
|
|
WO2002038738A2
(en)
|
2000-11-09 |
2002-05-16 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
|
DE60216798T2
(de)
*
|
2001-10-29 |
2007-10-18 |
Mcgill University, Montreal |
Azyklische linker enthaltende oligonukleotide und deren verwendungen
|
|
WO2003068934A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Rutter William J |
Chimeric molecules for cleavage in a treated host
|
|
US20080207542A1
(en)
|
2002-03-26 |
2008-08-28 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
|
SI2264172T1
(sl)
|
2002-04-05 |
2017-12-29 |
Roche Innovation Center Copenhagen A/S |
Oligomerne spojine za modulacijo izražanja HIF-1alfa
|
|
US20030228690A1
(en)
|
2002-06-10 |
2003-12-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of IL-1 receptor-associated kinase-1 expression
|
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
|
US20050130924A1
(en)
|
2002-06-26 |
2005-06-16 |
Monia Brett P. |
Antisense inhibition via RNAse H-independent reduction in mRNA
|
|
WO2004043979A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
EP1592795A2
(en)
|
2003-02-10 |
2005-11-09 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of ras expression
|
|
FR2853663B1
(fr)
|
2003-04-14 |
2007-08-31 |
Aventis Pharma Sa |
Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
|
|
WO2004112565A2
(en)
|
2003-06-25 |
2004-12-29 |
Quark Biotech, Inc. |
Diagnosis and treatment of liver, pulmonary and cardiac fibrosis
|
|
EP2530157B1
(en)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of miRNAs
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
CN101454451A
(zh)
|
2003-10-30 |
2009-06-10 |
科勒制药有限公司 |
具有增强免疫刺激能力的c类寡核苷酸类似物
|
|
US7431915B2
(en)
*
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
|
JP4642775B2
(ja)
*
|
2003-12-23 |
2011-03-02 |
サンタリス ファーマ アー／エス |
Ｂｃｌ−２のモデュレーションのためのオリゴマー化合物
|
|
US20050234002A1
(en)
|
2004-01-23 |
2005-10-20 |
Mourich Dan V |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
EP2330111A3
(en)
|
2004-01-30 |
2011-08-17 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
|
WO2005094370A2
(en)
|
2004-03-29 |
2005-10-13 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
|
EP1752536A4
(en)
|
2004-05-11 |
2008-04-16 |
Alphagen Co Ltd |
POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
|
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
DE102005036654A1
(de)
|
2005-08-04 |
2007-02-15 |
Bayer Materialscience Ag |
Selbstvernetzende PUR-Dispersionen mit Uretdionstruktur
|
|
JP5078904B2
(ja)
|
2005-11-21 |
2012-11-21 |
ジヨンソン・アンド・ジヨンソン・リサーチ・ピーテイワイ・リミテツド |
多標的干渉ｒｎａならびにそれらの使用および設計方法
|
|
WO2007133812A2
(en)
|
2005-12-30 |
2007-11-22 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Improved carriers for delivery of nucleic acid agents to cells and tissues
|
|
US8129515B2
(en)
|
2006-01-27 |
2012-03-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
|
WO2007091269A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Quark Pharmaceuticals, Inc. |
NOVEL TANDEM siRNAS
|
|
DK2666859T3
(en)
|
2006-04-03 |
2019-04-08 |
Roche Innovation Ct Copenhagen As |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
|
|
DK2021472T3
(da)
|
2006-05-05 |
2011-09-19 |
Isis Pharmaceuticals Inc |
Forbindelser og fremgangsmåder til modulering af genekspression
|
|
WO2008029619A1
(fr)
|
2006-09-07 |
2008-03-13 |
Daiichi Sankyo Company, Limited |
Oligonucléotide antisens ena ayant une action spécifique de la séquence
|
|
CA2667055C
(en)
|
2006-10-18 |
2017-05-09 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
WO2008109105A2
(en)
|
2007-03-06 |
2008-09-12 |
Flagship Ventures |
Methods and compositions for improved therapeutic effects with sirna
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
MX2010001785A
(es)
|
2007-08-15 |
2010-03-10 |
Idera Pharmaceuticals Inc |
Moduladores de receptores tipo larga distancia.
|
|
WO2009046397A2
(en)
|
2007-10-04 |
2009-04-09 |
Board Of Regents, The University Of Texas System |
Modulating gene expression with agrna and gapmers targeting antisense transcripts
|
|
ES2463665T3
(es)
|
2007-10-04 |
2014-05-28 |
Stella Aps |
Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
|
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2268813A4
(en)
|
2008-04-07 |
2012-10-10 |
Univ Queensland |
RNA MOLECULES AND USES THEREOF
|
|
CA2635187A1
(en)
|
2008-06-05 |
2009-12-05 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Oligonucleotide duplexes and uses thereof
|
|
US20110172292A1
(en)
|
2008-06-30 |
2011-07-14 |
Hansen Jens Bo Rode |
Antidote oligomers
|
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Curna, Inc. |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
EP2349210B1
(en)
|
2008-10-16 |
2015-03-18 |
Marina Biotech, Inc. |
Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
|
|
WO2010083615A1
(en)
|
2009-01-26 |
2010-07-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
US20120016007A1
(en)
|
2009-02-04 |
2012-01-19 |
Dong Ki Lee |
Small interference rna complex with increased intracellular transmission capacity
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2010120969A1
(en)
*
|
2009-04-15 |
2010-10-21 |
Board Of Regents, The University Of Texas System |
Targeting of the mir-30 family and let-7 family as a treatment for heart disease
|
|
JP2012533587A
(ja)
|
2009-07-22 |
2012-12-27 |
セニックス バイオサイエンス ゲーエムベーハー |
自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
|
|
SI2470656T1
(sl)
*
|
2009-08-27 |
2015-07-31 |
Idera Pharmaceuticals, Inc. |
Sestavek za inhibicijo ekspresije genov in njegova uporaba
|
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
|
EP2516647B1
(en)
|
2009-12-24 |
2016-12-14 |
BioMarin Technologies B.V. |
Molecule for treating an inflammatory disorder
|
|
EP2550360B1
(en)
*
|
2010-03-24 |
2017-08-30 |
Mirrx Therapeutics A/s |
Bivalent antisense oligonucleotides
|
|
EP2558578B1
(en)
|
2010-04-13 |
2015-10-28 |
Life Technologies Corporation |
Compositions and methods for inhibition of nucleic acids function
|
|
CA2796633C
(en)
*
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
HRP20170737T1
(hr)
|
2010-04-29 |
2017-07-28 |
Ionis Pharmaceuticals, Inc. |
Modulacija ekspresije transtiretina
|
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHOD FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
|
GB201010557D0
(en)
|
2010-06-23 |
2010-08-11 |
Mina Therapeutics Ltd |
RNA molecules and uses thereof
|
|
EP3489360A3
(en)
|
2010-07-19 |
2019-08-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
US8557787B2
(en)
|
2011-05-13 |
2013-10-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
|
|
JP6129844B2
(ja)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
|
CN108715594B
(zh)
|
2012-03-04 |
2020-12-04 |
株式会社博纳克 |
微小rna抑制剂
|
|
CA2873776A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating pten expression
|
|
WO2013173647A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating apoa1 and abca1 expression
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
JP2015523853A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ａｔｐ２ａ２発現を調節するための組成物及び方法
|
|
CN104583398A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节基因表达的组合物和方法
|
|
US9567581B2
(en)
*
|
2012-08-07 |
2017-02-14 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive X chromosome
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
SG10201804331TA
(en)
|
2012-11-15 |
2018-07-30 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
|
AU2015346042A1
(en)
|
2014-11-14 |
2017-04-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|